title: Long-term outcomes of peripheral blood stem cell transplantation for 38 patients with peripheral T-cell lymphoma.
abstract: OBJECTIVE
  In this study, to investigate clinical characteristics, response, outcome, and prognosis of peripheral blood stem cell transplantation (PBSCT) for patients with peripheral T-cell lymphoma (PTCL).
  
  
  METHODS
  This study retrospectively analyzed the efficacy of PBSCT in 38 patients with PTCL. Kaplan-Meier methods were used in survival analysis, and the Cox regression model was applied in multivariate analysis. There were ten clinical parameters were analyzed.
  
  
  RESULTS
  The 2-year overall survival (OS) was 46%, and the 5-year OS was 34% after a median follow-up of 40 months. The patients who received allogeneic PBSCT (allo-PBSCT) had a higher nonrelapse mortality than autologous PBSCT (auto-PBSCT), but they could achieve a longer-term disease-free survival in the former, which OS could achieve 40%. Survival analysis with Kaplan-Meier method showed the pretransplant disease status, B symptoms, serum lactate dehydrogenase (LDH) in early (>275 U/L), Eastern Cooperative Oncology Group (ECOG) score (>1), prognostic index for PTCL score (>2) were all prognostic factors for posttransplant OS. Pretransplant disease status is the only prognostic factor for allo-PBSCT.
  
  
  CONCLUSIONS
  The key was to reducing transplant-related mortality of allo-PBSCT by reduced-intensity conditioning. Factors such as level of early serum LDH, extranodal involvement, B symptoms, ECOG score, Ann Arbor stage, and pretransplant disease status were all related to the prognosis of patients treated with PBSCT. Allo-PBSCT maybe suggested as the first line therapy for late-stage PTCL patients who could reach treatment remission before transplantation.
authors.affiliation: Department of Hematology, Chinese People's Liberation Army General Hospital, Beijing 100853, China.
authors.forename: Jian
authors.initials: J
authors.lastname: Bo
authors.affiliation: Department of Hematology, Chinese People's Liberation Army General Hospital, Beijing 100853, China.
authors.forename: Yu
authors.initials: Y
authors.lastname: Zhao
authors.affiliation: Department of Hematology, Chinese People's Liberation Army General Hospital, Beijing 100853, China.
authors.forename: Songsong
authors.initials: S
authors.lastname: Zhang
authors.affiliation: Department of Hematology, Chinese People's Liberation Army General Hospital, Beijing 100853, China.
authors.forename: Wenrong
authors.initials: W
authors.lastname: Hua
authors.affiliation: Department of Hematology, Chinese People's Liberation Army General Hospital, Beijing 100853, China.
authors.forename: Shuhong
authors.initials: S
authors.lastname: Wang
authors.affiliation: Department of Hematology, Chinese People's Liberation Army General Hospital, Beijing 100853, China.
authors.forename: Chunji
authors.initials: C
authors.lastname: Gao
authors.affiliation: Department of Hematology, Chinese People's Liberation Army General Hospital, Beijing 100853, China.
authors.forename: Quanshun
authors.initials: Q
authors.lastname: Wang
authors.affiliation: Department of Hematology, Chinese People's Liberation Army General Hospital, Beijing 100853, China.
authors.forename: Honghua
authors.initials: H
authors.lastname: Li
authors.affiliation: Department of Hematology, Chinese People's Liberation Army General Hospital, Beijing 100853, China.
authors.forename: Li
authors.initials: L
authors.lastname: Yu
mesh_terms: D000293:Adolescent; D000328:Adult; D015415:Biomarkers; D002423:Cause of Death; D002648:Child; D003131:Combined Modality Therapy; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D016411:Lymphoma, T-Cell, Peripheral / Q000175:diagnosis / Q000401:mortality* / Q000628:therapy*; D008875:Middle Aged; D009367:Neoplasm Staging; D036102:Peripheral Blood Stem Cell Transplantation / Q000009:adverse effects / Q000379:methods; D011379:Prognosis; D016019:Survival Analysis; D019172:Transplantation Conditioning; D014182:Transplantation, Autologous; D014184:Transplantation, Homologous; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D015415:Biomarkers